Who developed Herceptin?

Herceptin was developed by Genentech, Inc., a biotechnology company based in South San Francisco, California, that is now a wholly-owned subsidiary of Roche. Scientists at Genentech, led by Dr. Axel Ullrich and Dr. H. Michael Shepard, identified the HER2 protein as a cancer target and developed trastuzumab, the active ingredient in Herceptin. Roche acquired a majority stake in Genentech in 1990 and completed full acquisition in 2009 for approximately $46.8 billion.

Is Herceptin publicly traded?

Herceptin is not publicly traded as a separate entity. Its owner, Roche, trades on the SIX Swiss Exchange under ROG and on the OTCQX market under RHHBY. Roche reported revenues of approximately 58.7 billion Swiss francs in fiscal year 2024. Investors seeking exposure to Herceptin's commercial performance must purchase shares in Roche.

What is Herceptin used for?

Herceptin is approved for the treatment of HER2-positive breast cancer (both metastatic and early-stage) and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers overexpress the HER2 protein, which drives tumor growth. Herceptin works by binding to the HER2 receptor, blocking its signaling and triggering immune-mediated destruction of HER2-positive cancer cells.

Healthcare & Pharmaceuticals

Who Owns Herceptin?

Q: Are there biosimilars of Herceptin?

Yes, multiple trastuzumab biosimilars are approved in the United States, including Ogivri (Mylan/Biocon, approved December 2017), Kanjinti (Amgen), Trazimera (Pfizer), Herzuma (Celltrion), and Ontruzant (Samsung Bioepis). These biosimilars are approved for the same indications as Herceptin and are typically priced at discounts to the reference product.

Herceptin (trastuzumab) is owned by Roche (SIX: ROG; OTCQX: RHHBY), a publicly traded Swiss multinational pharmaceutical and diagnostics company headquartered in Basel, Switzerland. Herceptin was developed by Genentech, a Roche subsidiary headquartered in South San Francisco, California. The FDA approved Herceptin on September 25, 1998, making it the first HER2-targeted therapy approved for breast cancer. Herceptin transformed the treatment of HER2-positive breast cancer, which accounts for approximately 15-20% of all breast cancers. Multiple biosimilars of trastuzumab are now approved in the United States, including Kanjinti, Ogivri, Trazimera, Herzuma, and Ontruzant. Herceptin generated peak annual revenues of approximately $7 billion globally before biosimilar entry eroded its market share.

Parent Company

Roche

Founded

1998

Status

Publicly Traded

Headquarters

Basel, Switzerland (Roche) / South San Francisco, California, USA (Genentech)

Herceptin Timeline

1896

Roche

Parent company established in Basel, Switzerland

Company Founded

1998

Herceptin

Founded by Genentech (developer; Roche subsidiary)

Founded

premiumpremiumGlobalall-agesOfficial Website

Who Owns Herceptin?

Parent Company: Roche
Ownership Type: Wholly owned
Company Type: Publicly Traded
Stock Ticker: SIX: ROG

Brand	Parent Company	Ownership Type
Herceptin	Roche	Wholly owned

Where to Buy

Disclosure: We may earn commission from purchases

Herceptin on Amazon

History of Herceptin

Founded: 1998
Founders: Genentech (developer; Roche subsidiary)

Herceptin's development originated from research at Genentech into the HER2 protein, a receptor tyrosine kinase that is overexpressed in approximately 15-20% of breast cancers. Scientists at Genentech, led by Dr. Axel Ullrich and Dr. H. Michael Shepard, identified that HER2 overexpression was associated with more aggressive breast cancer and poorer prognosis, and hypothesized that targeting HER2 with a monoclonal antibody could slow or stop the growth of HER2-positive tumors.

Genentech developed trastuzumab, a humanized monoclonal antibody that binds to the extracellular domain of the HER2 receptor, blocking its signaling and triggering immune-mediated destruction of HER2-positive cancer cells. Clinical trials demonstrated that trastuzumab significantly improved survival in women with HER2-positive metastatic breast cancer, particularly when combined with chemotherapy.

The FDA approved Herceptin on September 25, 1998, for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein. The approval was accompanied by the simultaneous approval of the first companion diagnostic test for HER2 overexpression, establishing the model of biomarker-driven cancer therapy that has become standard practice in oncology. Herceptin was one of the first targeted cancer therapies approved by the FDA and represented a paradigm shift in cancer treatment.

Following the initial approval for metastatic breast cancer, Herceptin received additional FDA approvals for early-stage HER2-positive breast cancer (adjuvant therapy, 2006) and for HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma (2010). These expanded indications significantly broadened Herceptin's patient population and commercial potential.

Herceptin became one of the best-selling cancer drugs in history, generating peak annual revenues of approximately $7 billion globally. The drug's commercial success funded Genentech's and Roche's continued investment in HER2-targeted therapies, leading to the development of Perjeta (pertuzumab, approved 2012) and Kadcyla (ado-trastuzumab emtansine, approved 2013), which are used in combination with or as successors to Herceptin in various HER2-positive breast cancer settings.

Herceptin's U.S. patents began expiring in the mid-2010s, opening the door for biosimilar competition. The FDA approved the first trastuzumab biosimilar, Ogivri (trastuzumab-dkst, Mylan/Biocon), in December 2017. Multiple additional biosimilars have since been approved, including Kanjinti (Amgen), Trazimera (Pfizer), Herzuma (Celltrion), and Ontruzant (Samsung Bioepis). The entry of biosimilars has significantly reduced Herceptin's market share and revenues, as biosimilars are typically priced at a discount to the reference product.

Despite biosimilar competition, Herceptin remains an important treatment option for HER2-positive breast cancer and gastric cancer patients globally, particularly in markets where biosimilars have not yet achieved significant penetration.

About Roche

Roche operates through two main business divisions: Pharmaceuticals and Diagnostics, creating a unique integrated healthcare company that combines treatment and diagnostic capabilities. This dual focus enables Roche to deliver personalized healthcare solutions, matching patients with the most effective treatments based on diagnostic information and molecular characteristics.

The Pharmaceuticals division develops and manufactures prescription medicines across multiple therapeutic areas, with particular strength in oncology, immunology, neuroscience, infectious diseases, and rare diseases. Roche's pharmaceutical portfolio includes both established blockbuster products and innovative new treatments that address significant unmet medical needs. The division maintains a global research and development network with facilities across multiple continents, investing billions annually in pharmaceutical innovation, clinical trials, and regulatory approvals.

The Diagnostics division produces laboratory testing systems, molecular diagnostics, and point-of-care testing devices that support healthcare professionals in disease detection, monitoring, and treatment selection. Roche's diagnostic capabilities include automated laboratory systems, molecular testing platforms, and digital health solutions. The division's integrated approach with pharmaceuticals creates unique advantages in personalized medicine, enabling precise treatment selection based on diagnostic information.

Roche's business philosophy emphasizes innovation, patient-centricity, and sustainable value creation. The company maintains a strong focus on research and development, with approximately 20% of pharmaceutical revenues invested in R&D activities. This investment supports a robust pipeline of new treatments and diagnostic solutions, with 10 key molecules advancing into phase III development in 2025 alone.

Financial performance in 2025 demonstrated the strength of Roche's integrated business model. The company reported 7% sales growth at constant exchange rates to CHF 61.5 billion, with the Pharmaceuticals Division achieving 9% growth and the Diagnostics Division growing 2%. Core operating profit increased by 13%, reflecting operational efficiency and strong demand for both pharmaceutical and diagnostic solutions.

Key growth drivers in 2025 included Phesgo for breast cancer, Xolair for food allergies, Ocrevus for multiple sclerosis, Hemlibra for hemophilia A, and Vabysmo for severe eye diseases. These products demonstrate Roche's strength across multiple therapeutic areas and its ability to deliver innovative treatments that address significant patient needs.

Looking toward 2026, Roche expects Group sales growth in the mid single digit range and core earnings per share growth in the high single digit range at constant exchange rates. The company plans to further increase its dividend to CHF 9.80 per share, which would mark the 39th consecutive dividend increase if approved by shareholders. For 2026, Roche is shifting focus from consolidation to optimization, emphasizing internal pipeline development and R&D process improvements to enhance productivity and decision-making.

Roche's strategic priorities include investing in programs with potential to redefine care standards, particularly in oncology, neuroscience, and immunology. The company maintains a $10 billion annual budget for potential acquisitions and partnerships, prioritizing strategic fit and scientific differentiation over transaction size. This approach reflects Roche's commitment to long-term value creation and sustainable growth while maintaining operational discipline.

Founded: 1896
Headquarters: Basel, Switzerland
Company Type: Publicly Traded
Stock: SIX: ROG
Revenue: CHF 61.5 billion (FY2025)
Employees: Approximately 101,000

Visit Roche website

View full company profile for Roche

Where Is Herceptin Made / Based?

Headquarters: Basel, Switzerland (Roche) / South San Francisco, California, USA (Genentech)
Manufacturing / Operations: United States, Switzerland, Germany

Herceptin Categories & Tags

Oncology Breast Cancer Her2 Trastuzumab Biologic

Herceptin Sustainability & Ethics

Herceptin's sustainability and ethics considerations are governed by Roche's corporate sustainability framework, which covers environmental responsibility in biopharmaceutical manufacturing, patient access programs, and ethical clinical research practices.

Manufacturing and Environmental Compliance: Herceptin is produced at Genentech's Vacaville, California facility and Roche's sites in Basel, Switzerland, and Penzberg, Germany. These facilities operate under strict environmental regulations and pharmaceutical industry standards. Roche implements environmental management systems including energy-efficient bioreactor operations, water conservation, and waste reduction at its manufacturing sites.

Patient Access: Herceptin's high cost as a specialty biologic therapy has generated controversy regarding patient access and healthcare system costs. Roche implements patient assistance programs, tiered pricing strategies, and partnerships with healthcare organizations to improve access in both developed and developing markets. Herceptin is included on the WHO Essential Medicines List, which supports its availability in global health systems.

Clinical Research Ethics: Roche maintains ethics review processes, informed consent procedures, and patient safety monitoring systems for all Herceptin-related clinical research and post-marketing surveillance. The drug's more than 25 years of clinical use have generated an extensive body of safety and efficacy data.

Herceptin has not received independent third-party sustainability certifications specific to the product. Roche publishes an annual sustainability report covering environmental performance, access to healthcare, and ethical business practices across its portfolio, available on Roche's corporate website.

Awards & Recognition

First HER2-Targeted Therapy (1998): Herceptin was the first HER2-targeted therapy approved by the FDA for breast cancer, establishing the paradigm of biomarker-driven targeted cancer therapy.
WHO Essential Medicines List: Herceptin is included on the World Health Organization's Essential Medicines List, recognizing it as one of the most effective and safe medicines needed in a health system.
Companion Diagnostic Pioneer: The simultaneous FDA approval of Herceptin and the first HER2 companion diagnostic test in 1998 established the model for biomarker-driven cancer therapy that has become standard practice in oncology.
Lasker-DeBakey Clinical Medical Research Award (2019): Dr. H. Michael Shepard, one of the Genentech scientists who developed Herceptin, shared the 2019 Lasker-DeBakey Clinical Medical Research Award for the invention of HER2-targeted therapy.

Herceptin Recalls & Controversies

Pricing and Access Controversies: Herceptin's high price point, typical of specialty biologic therapies, has generated controversy regarding patient access and healthcare system costs. Patient advocacy groups and healthcare payers have criticized the drug's annual treatment costs, particularly in markets with limited insurance coverage or government healthcare systems. Roche has implemented patient assistance programs and tiered pricing to address access concerns.

Biosimilar Competition and Patent Disputes: The entry of trastuzumab biosimilars has generated controversy regarding intellectual property, market exclusivity, and patient safety. Roche has faced criticism from biosimilar manufacturers and patient groups regarding efforts to maintain market share and protect patent rights, while biosimilar companies have faced questions about demonstrating therapeutic equivalence.

Cardiac Safety Concerns: Herceptin carries a known risk of cardiotoxicity, particularly when used in combination with anthracycline chemotherapy. This safety concern requires appropriate patient selection, cardiac monitoring during treatment, and careful risk-benefit assessment. The cardiac safety profile has been extensively studied and is well-characterized in the drug's labeling, but remains a consideration in treatment decisions.

Manufacturing and Supply Issues: Herceptin's complex biopharmaceutical manufacturing process has occasionally faced challenges related to production capacity and supply chain disruptions. These issues have generated concern regarding drug availability and patient access during periods of manufacturing constraints.

Clinical Trial Design Scrutiny: Some aspects of Herceptin's clinical development program have faced scrutiny from the medical community regarding trial design, endpoint selection, and statistical analysis. These debates reflect broader methodological discussions in oncology research rather than specific issues with Herceptin's clinical evidence.

Herceptin Ownership: Pros & Cons

Advantages

+Herceptin's status as the original and reference HER2-targeted therapy, with more than 25 years of clinical use and an extensive body of clinical evidence, provides physician familiarity and patient trust that biosimilars and newer competitors must overcome
+The drug's role as the foundation of HER2-positive breast cancer treatment, often used in combination with Perjeta and chemotherapy in neoadjuvant and adjuvant settings, ensures continued clinical relevance
+Roche's global manufacturing infrastructure and established supply chain for trastuzumab provide reliable product availability across developed and developing markets
+Herceptin's approval for HER2-positive gastric cancer in addition to breast cancer provides a second major oncology indication
+Roche's companion diagnostic infrastructure, including HER2 testing assays, supports identification of patients who are candidates for Herceptin

Considerations

-Multiple trastuzumab biosimilars approved in the United States and other major markets have significantly eroded Herceptin's market share and revenues, as biosimilars are typically priced at 15-35% discounts to the reference product
-Next-generation HER2-targeted therapies, particularly AstraZeneca/Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), have demonstrated superior efficacy to Herceptin in certain settings, potentially displacing Herceptin in those indications over time
-Herceptin's requirement for intravenous infusion, typically administered every three weeks, creates a treatment burden for patients that subcutaneous or oral HER2-targeted therapies may reduce
-Herceptin's primary risk of cardiotoxicity requires cardiac monitoring during treatment, limiting its use in patients with pre-existing cardiac conditions
-Loss of patent exclusivity and biosimilar competition have fundamentally changed Herceptin's commercial trajectory, with revenues declining significantly from peak levels

Frequently Asked Questions About Herceptin

Sources & Further Reading

Competitors to Herceptin

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
PerjetaSister Brand	Roche	USA (Genentech)	2012	Premium	Global	Womens
KadcylaSister Brand	Roche	Switzerland	2013	Mass market	Global	All Genders
AvastinSister Brand	Roche	Switzerland	2004	Premium	Global	Unisex
Keytruda	Merck	USA	2014	Mass market	Global	All Genders
RituxanSister Brand	Roche	USA (Genentech)	1997	Mass market	Global	All Genders
Taxotere	Sanofi	France	1996	Established	Global	Unisex